Compugen (NASDAQ:CGEN) Announces Quarterly Earnings Results

Compugen (NASDAQ:CGEN) issued its quarterly earnings results on Tuesday. The biotechnology company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.20), Zacks reports. Compugen had a return on equity of 2.61% and a net margin of 2.67%. The company had revenue of $17.13 million for the quarter, compared to the consensus estimate of $17.67 million. During the same period in the previous year, the business posted ($0.11) EPS.

Compugen Stock Performance

NASDAQ CGEN traded down $0.01 during trading on Wednesday, reaching $1.59. 262,108 shares of the company traded hands, compared to its average volume of 406,589. The stock’s 50 day moving average price is $1.77 and its two-hundred day moving average price is $1.88. The company has a market cap of $141.89 million, a price-to-earnings ratio of 80.50 and a beta of 2.64. Compugen has a 1-year low of $0.55 and a 1-year high of $3.03.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.